Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Aereo Announces Launch Date for Austin
Date : 02/24/2014 @ 7:30AM
Source : Marketwired
Aereo Announces Launch Date for Austin
PrintAlert
Aereo Announces Launch Date for Austin
Starting March 3, More Than 1.25 Million Consumers in Greater Austin Will Have Access to Aereo's Innovative Antenna/DVR Technology to Record and Watch Live Television Online
NEW YORK, NY--(Marketwired - Feb 24, 2014) - Aereo, Inc., today announced plans to launch its groundbreaking remote antenna/DVR television technology in the Greater Austin area on March 3. Greater Austin is Aereo's 4th market to launch in Texas and includes a 12-county area.
"We're excited to launch in Austin, our fourth Texas market," said Aereo CEO and Founder Chet Kanojia. "Aereo's innovative cloud-based antenna/DVR technology brings the old-fashioned antenna into the 21st Century, providing consumers access to the over-the-air broadcast signals that belong to them. Aereo makes using an antenna easy again -- the way it should be. We're looking forward to kicking off in Austin."
Greater Austin residents who pre-register at Aereo.com will receive priority access to sign up. Aereo's technology will be available to all consumers across the 12-county area on March 3.
Aereo's innovative remote (cloud-based) antenna/DVR technology makes watching television simple and user-friendly. Using Aereo's technology, consumers can pause and rewind any program that they are watching live, or save a program for future viewing.
In the Greater Austin region, consumers will be able to use Aereo's unique antenna/DVR technology to record and watch 19 over-the-air channels including major networks such as KVUE (ABC), KXAN (NBC), KEYE (CBS), KTBC (Fox), KNVA (CW) and KLRU (PBS); special interest channels ThisTV, MOVIES!, GetTV, Create TV and AccuWeather; and Spanish-language channels UniMás, UniVision, Telemundo and Estrella TV. In addition, consumers will also have the ability to add Bloomberg Television.
Aereo membership begins at $8 per month, for access to Aereo's cloud-based antenna/DVR technology and 20 hours of DVR storage. For an additional $4, consumers can upgrade their membership and receive 60 hours of DVR storage for a total of $12 per month. Consumers who join Aereo will get their first of month of access for free.
Aereo membership will be available to consumers residing in the following 12 counties in Texas: Bastrop, Blanco, Burnet, Caldwell, Fayette, Gillespie, Hays, Lee, Llano, Mason, Travis and Williamson.
Aereo's technology works on 'smart' devices from tablets to phones to laptop computers. Aereo is currently supported on iPad, iPhone, iPod Touch. The Aereo app for Androidâ„¢ (currently in beta) is available for download for devices running Android operating system version 4.1 or higher. Aereo is also supported on Chrome, Safari, Internet Explorer 9, Firefox, Opera, AppleTV (via airplay) and Roku platforms.
To learn more about Aereo's technology and how to pre-register, visit Aereo.com.
For media inquiries:
Virginia Lam, Aereo, Inc.
vlam@aereo.com
press@aereo.com
LaunchSquad for Aereo
aereo@launchsquad.com
(212) 564-3665
Marina Biotech Announces $6 MM Convertible Preferred Stock Financing & Conversion to Common Stock of the Company's Promissory...
Date : 02/24/2014 @ 7:30AM
Source : Marketwired
Stock : Marina Biotech, Inc. (PL) (MRNA)
Quote : 1.27 0.0 (0.00%) @ 6:50AM
Marina Biotech Announces $6 MM Convertible Preferred Stock Financing & Conversion to Common Stock of the Company's Promissory...
PrintAlert
Marina Biotech, Inc. (PL) (USOTC:MRNA)
Intraday Stock Chart
Today : Monday 24 February 2014
Marina Biotech Announces $6 MM Convertible Preferred Stock Financing and Conversion to Common Stock of the Company's Promissory Note
Company to Advance Its Preclinical and Clinical Rare Disease Programs
BOSTON, MA--(Marketwired - Feb 24, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company focused on rare diseases, announced today that it has entered into a binding term sheet with certain qualified investors, led by Steven T. Newby, a long-time biotechnology investor, for the issuance of convertible preferred stock at a conversion price equivalent to $0.75 per share of common stock resulting in gross proceeds of $6 million. In addition, the Company will issue to the investors warrants to purchase 6 million shares of common stock. The warrants will have an exercise price of $0.75 per share and are exercisable for a period of five years after the Company regains compliance with its reporting obligations under the Securities Exchange Act. The offering is expected to close on or about March 7, 2014, subject to the execution of a customary Securities Purchase Agreement regarding the transaction and the satisfaction of customary closing conditions. The Company also announced that the holders of the Company's Promissory Note have agreed to convert the remaining principal and interest on the Note to common stock at a conversion price of $0.75 and release their lien on the Company's intellectual property. Proceeds from the financing will be used to restart certain day-to-day operations, repay the Company's outstanding obligations, regain compliance with the Company's Exchange Act reporting obligations and advance the Company's preclinical and clinical rare disease programs.
"I believe this investment provides the catalyst which will significantly change the trajectory of the Company," stated J. Michael French, President and CEO at Marina Biotech. "This is the first equity financing we have closed in nearly two years and involves an extremely knowledgeable investor known for his long-term view in the biotechnology sector. With the conversion of the remaining principal and interest on the Company's Promissory Note to common stock, we not only regain all rights to our intellectual property estate but we can apply the entire $6 million to our on-going operations. These proceeds will be used to regain compliance with our reporting obligations under the Exchange Act thereby providing us the opportunity to explore up-listing to a national securities exchange; pursue licensing and partnering opportunities with large pharmaceutical companies; settle existing liabilities; reestablish key strategic partnerships and alliances; and establish our offices in the Boston area. Most importantly, we now have the ability to focus on, and advance, our preclinical and clinical rare disease programs. We will analyze cohort 2 data from our START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) trial to look for knock-down of the therapeutic target gene as well as initiate animal testing in our preclinical program in myotonic dystrophy. Since we are transitioning from a primarily research focused company to a primarily development focused company, we intend to create a small initial footprint in the Boston area and keep our operating costs at a minimum. We will utilize contract research organizations as well as academic centers to advance our rare disease programs and therefore will require only a nominal laboratory operation until we establish a sponsored research and development collaboration with a partner. This will permit us to focus our available resources on our preclinical and clinical programs while continuing to build the premier nucleic acid therapeutics company in the rare disease sector."
About Marina Biotech, Inc.
Marina Biotech is an oligonucleotide therapeutics company with a broad drug discovery platform providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messengerRNA therapeutics. The platform was built via a roll-up strategy to discover and develop different types of nucleic acid therapeutics in order to modulate (up or down) a specific protein(s) which is either being produced too much or too little thereby causing a particular disease. We believe that the Marina Biotech platform has unique strengths as a drug discovery engine for the development of nucleic acid-based therapeutics for rare and orphan diseases. Further, we believe Marina is the only company in the sector that has a delivery technology in human clinical trials with differentiated classes of payloads, through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. Our novel chemistries and other delivery technologies have been validated through license agreements with Roche, Novartis, Monsanto, and Tekmira. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and myotonic dystrophy. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at www.marinabio.com.
Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Marina Biotech, Inc.
J. Michael French
President and Chief Executive Officer
(425) 892-4322
admin@marinabio.com
ARIAD to Present at the Cowen and Company 34th Annual Health Care Conference
Date : 02/24/2014 @ 7:35AM
Source : Business Wire
Stock : Ariad Pharmaceuticals, Inc. (MM) (ARIA)
Quote : 8.87 0.14 (1.60%) @ 7:24AM
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Cowen and Company 34th Annual Health Care Conference being held in Boston. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Tuesday, March 4, at 10:40 a.m. (ET).
The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor. A replay of the presentation will also be available and archived on the site for three weeks.
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
MHYS, THIS POST indicateds the person putting out that report created his ID almost same day. Might be misleading.
Thanks Hack I have put that in my keepers!
Hack, can you explain the tweezer bottoms and what they indicate?
Might want to keep and eye on LUSI as well. Closed yesterday at 0.0001, opened today at 0.0002 with some 0.0003's selling today. 76 million vol and Trader53 alerted it today from the Trip000 board
I bought in on CYBL as well but did I not hear the MM/s that start with V were diluters?
Is there somewhere that lists the MMs and who to be aware of?
Come on guys let a looser in on the good secretes too. <WINK>
CYBL in @ 0.0002 for 1.5 milly
SM, how does a skype room work> I have skype but always thought that was video phone? Do you have to bave an ap or what?
Thanks!!!
Good morning. Ready for some breakfast>?
Top Stories
Facebook to buy WhatsApp for up to $19B. The sound of jaws collectively crashing onto the floors of trading rooms was heard across Wall Street yesterday - and probably far beyond - after Facebook (FB) said it has agreed to acquire WhatsApp for $19B in cash and shares. Although the mobile-messaging application has 450M monthly active users, the valuation is higher than that of 235 S&P 500 components. Still, as with Instagram, one theory seems to be that Facebook has paid heavily to head off what it sees as a potential major threat. Shares were -2.4% premarket.
ADVERTISEMENT
Trade FREE For 90 Days. Open and fund a new TradeStation brokerage account and get TradeStation FREE for the next 90 days. — Open an account >>
Chinese factory activity contracts at faster pace. China's flash manufacturing PMI has tumbled to a seven-month low of 48.3 in February from 49.5 in January and missed consensus of 49.4. The sub-indexes for output, new orders, new export orders and employment contracted. The fall in overall PMI adds to other data that provides a mixed picture of China's economy, although the latest figures may have been hampered by the Lunar New Year holiday.
Tesla Motors tears higher as guidance supports growth story. Tesla Motors' (TSLA) losses narrowed to $16.3M in Q4 from $89.9M a year earlier as revenue surged 101% to $615.29M. The figure missed consensus, although adjusted EPS of $0.33 beat by $0.12. Shares jumped 10.15%, with the electric car-maker providing an optimistic outlook for production and deliveries, especially overseas.
Top Stock News
Peltz renews attempt to break up PepsiCo. Nelson Peltz has sent a 37-page letter to PepsiCo's (PEP) board renewing his call for the company to spin off its struggling beverage business - which has been battling falling soda sales in developed markets - and focus on snack brands Lays, Cheetos and Doritos. The letter comes less than a week after PepsiCo ruled out a break-up following a review.
Weak PMIs hits global equities. Global equities were lower at the time of writing following disappointing PMI data out of China and the eurozone - particularly France - and a record trade deficit in Japan. Hawkishness in the latest FOMC minutes is also not helping. (See below for more details).
Merck consumer-healthcare ops attract several suitors - Reuters. Novartis (NVS) and Bayer (OTCPK:BAYRY) are among the suitors that are exploring an acquisition of Merck's (MRK) consumer-healthcare business, Reuters reports, adding that the unit could be worth $10-12B. Reckitt Benckiser (OTCPK:RBGPF) and Procter & Gamble (PG) are also among the companies to have held talks with Merck about a deal. However, GSK (GSK) is not interested.
Safeway eyes sale. Safeway (SWY) is "in discussions concerning a possible transaction involving the sale of the company," the supermarket chain said yesterday in tandem with the release of its Q4 earnings. EPS of $0.53 beat consensus by $0.05 but revenue slumped 18% to $11.3B and missed by $180M. Safeway is also exploring options for monetizing its 49% stake in Mexican grocery store chain Casa Ley, and it has decided to distribute its 72.2% holding in Blackhawk Network (HAWK) to shareholders.
BlackBerry jumps following Facebook/WhatsApp deal. BlackBerry (BBRY) was +6.8% following news that Facebook (FB) is acquiring WhatsApp. Investors are betting the deal will spell a higher valuation for BBM, which had added 40M+ Android/iOS users as of December to go with its BlackBerry base.
H-P sales seen falling. H-P (HPQ) is due to report its FQ1 results after the bell, with analysts estimating that EPS rose to $0.85 from $0.82 a year earlier, while revenue slipped 4.1% to $27.19B as the company continued to struggle with sluggish corporate IT demand and the contracting PC market. "Despite some progress and stabilization, we continue to believe serious secular/competitive pressures in most of H-P's end markets are too difficult to overcome and remain concerned that the fiscal 2014 guidance...could prove optimistic," says ISI Group analyst Brian Marshall.
Top Economic & Other News
Eurozone business activity softens. Eurozone flash manufacturing PMI has slipped to 53 in February from 54 in January and undershot forecasts that were also 54. German growth slowed and France's contraction accelerated. The eurozone's services print has edged up, but the composite output has fallen to 52.7 from 52.9. "A dip in the eurozone PMI provides a reminder that the region's recovery continues to be uneven and fragile," says Markit, "but it's too early to read too much into one month's data."
Japanese trade deficit soars to record, shares slump. Japan's trade deficit more than doubled to a record ¥2.79T ($27.3B) in January from ¥1.3T in December and exceeded consensus of ¥2.49T. Export growth slowed while imports soared 25%. In Q4, a large trade deficit contributed to GDP expanding at a lower-than-expected 1%. However, the latest figures may have been affected by a rush to purchase foreign-made goods before a sales-tax increase in April and by the Chinese New Year.
FOMC minutes: A few see chance of rate hikes "relatively soon." In the last FOMC meeting chaired by Ben Bernanke, a few policy makers saw a chance of rate hikes "relatively soon." As for forward guidance in which the Fed promised to hold Fed Funds near 0% after the 6.5% unemployment rate threshold was crossed - that's pretty much done with. The minutes also show little concern about the string of soft economic data at the start the year.
Nebraska judge's ruling threatens Keystone. In a victory for opponents of TransCanada's (TRP) Keystone pipeline, a Nebraska judge has quashed a law that allowed Governor Dave Heineman to approve the building of the pipeline through the state. The decision now rests with the Public Service Commission. Meanwhile, at the "Three Amigos" Nafta summit in Mexico, Canadian Prime Minister Stephen Harper appears to have made little headway in persuading President Obama to speed up a decision over whether to approve Keystone.
Top Ideas: Movers and Great Calls
1) On January 27, BuyTheDip SellTheRip called video-conferencing specialist Polycom (PLCM) a 2013 laggard that was set to outpace the market in 2014, based on cost-cutting, buybacks and the introduction of new products. Shares are +10.6% since. Read article »
2) Dennis Beaudet cited a massively undervalued concession in Kenya in recommending oil and gas explorer Taipan Resources (OTC:TAIPF) in December. After an updated estimate showed a nearly 4x gain in prospective resources, the stock is +86.6% since Beaudet's recommendation. Read article »
Top Ideas To Watch
1) Overstated fears of a collapse in mortgage originations have led to a buying opportunity in Walter Investment Management (WAC), writes Ashleigh Rogers. Read article »
2) Helix Investment Research says Air Canada's (OTCPK:AIDIF) stock is set to soar as currency headwinds and fleet-expansion costs abate, leading to margin and earnings growth. Read article »
Top Idea articles are the best long and short ideas on Seeking Alpha. SA PRO subscribers receive early access to these Top Idea articles, which often move markets. For more information about SA PRO and becoming a subscriber, click here.
Today's Markets:
In Asia, Japan -2.1% to 14449. Hong Kong -1.2% to 22394. China -0.2% to 2139.
In Europe, at midday, London -0.2%. Paris -0.5%. Frankfurt -1.1%.
Futures at 6:20: Dow -0.1%. S&P -0.1%. Nasdaq -0.1%. Crude -0.1% to $103.17. Gold -0.5% to $1313.50.
Ten-year Treasury Yield -2 bps to 2.73%
Today's economic calendar:
8:30 Consumer Price Index
8:30 Initial Jobless Claims
9:00 PMI Manufacturing Index Flash
9:45 Bloomberg Consumer Comfort Index
10:00 Philly Fed Business Outlook
10:00 Leading Indicators
10:30 EIA Natural Gas Inventory
11:00 EIA Petroleum Inventories
4:30 PM Money Supply
4:30 PM Fed Balance Sheet
Notable earnings before today's open: ACT, AER, CBB, CCO, CDE, CONE, CRIS, CRY, CVI, CVRR, CWEI, CYBX, DAN, DNR, DTV, ELOS, EXAS, FCN, FDML, FUN, HEP, HRL, HSC, HSNI, I, ICLR, ICON, IDCC, IMAX, IRC, LTM, LXP, MRGE, PAAS, PDCO, PEG, PWR, RS, SCG, SONS, SUI, THI, TK, TRP, TTC, UAN, UPL, WLK, WLT, WMT, WWE, YNDX
Notable earnings after today's close: ACTG, AGU, AHS, ANAD, ARUN, BBG, BCOR, BLDR, BLOX, CENX, COG, DTLK, DXCM, ESRX, EXEL, EXR, FLTX, FNGN, FUEL, GRPN, HNSN, HPQ, INAP, INTU, IPXL, JWN, KND, LOPE, MDRX, MHK, MRC, MRVL, MTSN, MXWL, NEM, PCLN, PEB, PPC, PSA, QLIK, SEM, SSRI, SSTK, TRMR, TS, TTS, VMI, WAGE, WBMD, WRE, XNPT
See full real-time earnings coverage »
Wall Street Breakfast
What is the ticker symbol?
You go PW!
Already holding 2 milly @ 0.0001 waiting for the pop!
Thanks to Trader53
So the news today indicates the A/S is now almost double to 6 billon shares?
That was a good joke@!
Volume preceeds price !
Good Morning, Another Trading day is upon us!
I am holding some free shares I have left from a position I took at 0.0009
Would love that. Be Watching
I didthe 30 day free trial on Equity Feed and LOVED the news screener. Could not justify the money at this time though. Trading full time I would almost have to call it a MUST though.
Hemo...got a blood thing going on hey?
Thanks Tony. I do plan on holding my investment in HEMP to see how this grows. (no pun)
I sure hope it does but the stock really has not been responding well to the good news out as some of the other's have. I hope the other are wrong because I am holding for the big moves coming.
Why does HEMP not move upon price ? Lots of good news. I am a little down but will take the loss if Tuesday is the blood bath I've heard .
Thanks for the great info!
Knew you would like that AT !
What caused that Spike? News?
Would that not be a 3 day weekend? Not 4
4 day (?) weekend?????
Obama just released banking regulations allowing them to work with pot companies.
http://www.cnbc.com/id/101418265
Happy Valentine's Day Everyone.
Have a great weekend!
Know what it is, just making little joke that my financial status doesn't allow for PRIME RIB.....maybe round steak or campfire special, beef, beans and wennies>
Prime Rib......what's that?????
Congrats on "falling into some weekend cash". +
MJ plays.....
FINRA warning on Marijuana Stock Scams - http://www.finra.org/investors/protectyourself/investoralerts/fraudsandscams/p325352
Of COURSE they are.....always late top the party, not a damn thing left to eat and they ask me to CLEAN UP!!! AHhhhhhhhhhhhhhhh!!!!!
HEMP - How come there is news and no PPS movement
Thank you for the chart Clay!